• Something wrong with this record ?

Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay

P. Barta, M. Volkova, A. Dascalu, D. Spiegelberg, F. Trejtnar, K. Andersson,

. 2014 ; 70 (2) : 145-51.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

INTRODUCTION: Competitive binding assays can be used to decipher not only the binding kinetics of studied ligands but also the binding site preference. Such assays are an essential step in the characterization of radioligands. However, the currently used competition assays require high concentrations of usually expensive ligands and still provide only binding site preference. By employing the time-resolved competition assay presented in this paper, binding characteristics including binding site preference can be obtained using less ligand. METHODS: To demonstrate the appropriateness of the time-resolved competition assay, we developed an assay in which the ligand binding was interrupted with a competitor. Experiments were performed on human carcinoma cell lines expressing epidermal growth factor receptor (EGFR). The targeting of the receptor was performed with radio-iodinated epidermal growth factor (EGF). The employed competitors involved either natural ligand transforming growth factor alpha (TGF-α) or anti-EGFR antibodies cetuximab and panitumumab targeting the same EGFR domain. RESULTS: Radio-iodinated EGF bound to EGFR was displaced with either low concentrations of cetuximab or high concentrations of panitumumab. In the case of TGF-α, we observed no competitive displacement of bound EGF at either high or low concentrations. When comparing the time-resolved competition assay with a manual competition assay, the resulting data of measured inhibition constants were in agreement. DISCUSSION: The results summarised in this study confirm the appropriateness of the time-resolved competition assay for assessing ligand binding properties. The assay has the potential to complement or replace conventional competition assays for determining binding site preference in the future.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023181
003      
CZ-PrNML
005      
20150730095141.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vascn.2014.07.006 $2 doi
035    __
$a (PubMed)25084055
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Barta, Pavel $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University in Prague, Hyerovskeho 1203, 50005 Hradec Kralove, Czech Republic. Electronic address: pavel.barta@faf.cuni.cz.
245    10
$a Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay / $c P. Barta, M. Volkova, A. Dascalu, D. Spiegelberg, F. Trejtnar, K. Andersson,
520    9_
$a INTRODUCTION: Competitive binding assays can be used to decipher not only the binding kinetics of studied ligands but also the binding site preference. Such assays are an essential step in the characterization of radioligands. However, the currently used competition assays require high concentrations of usually expensive ligands and still provide only binding site preference. By employing the time-resolved competition assay presented in this paper, binding characteristics including binding site preference can be obtained using less ligand. METHODS: To demonstrate the appropriateness of the time-resolved competition assay, we developed an assay in which the ligand binding was interrupted with a competitor. Experiments were performed on human carcinoma cell lines expressing epidermal growth factor receptor (EGFR). The targeting of the receptor was performed with radio-iodinated epidermal growth factor (EGF). The employed competitors involved either natural ligand transforming growth factor alpha (TGF-α) or anti-EGFR antibodies cetuximab and panitumumab targeting the same EGFR domain. RESULTS: Radio-iodinated EGF bound to EGFR was displaced with either low concentrations of cetuximab or high concentrations of panitumumab. In the case of TGF-α, we observed no competitive displacement of bound EGF at either high or low concentrations. When comparing the time-resolved competition assay with a manual competition assay, the resulting data of measured inhibition constants were in agreement. DISCUSSION: The results summarised in this study confirm the appropriateness of the time-resolved competition assay for assessing ligand binding properties. The assay has the potential to complement or replace conventional competition assays for determining binding site preference in the future.
650    _2
$a monoklonální protilátky $x chemie $x farmakologie $7 D000911
650    _2
$a humanizované monoklonální protilátky $x chemie $x farmakologie $7 D061067
650    _2
$a kompetitivní vazba $x účinky léků $7 D001667
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a epidermální růstový faktor $x chemie $x metabolismus $7 D004815
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a erbB receptory $x antagonisté a inhibitory $x chemie $x metabolismus $7 D066246
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a substrátová specifita $7 D013379
650    _2
$a časové faktory $7 D013997
650    _2
$a transformující růstový faktor alfa $x chemie $x metabolismus $7 D016211
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Volkova, Marie $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University in Prague, Hyerovskeho 1203, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Dascalu, Adrian $u Rudbeck Laboratory/BMS, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Dag Hammarskjölds väg 20, 75185, Uppsala, Sweden.
700    1_
$a Spiegelberg, Diana $u Rudbeck Laboratory/BMS, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Dag Hammarskjölds väg 20, 75185, Uppsala, Sweden.
700    1_
$a Trejtnar, Frantisek $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University in Prague, Hyerovskeho 1203, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Andersson, Karl $u Rudbeck Laboratory/BMS, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Dag Hammarskjölds väg 20, 75185, Uppsala, Sweden; Ridgeview Instruments AB, Skillsta 4, 74020 Vänge, Sweden. $7 gn_A_00006202
773    0_
$w MED00002898 $t Journal of pharmacological and toxicological methods $x 1873-488X $g Roč. 70, č. 2 (2014), s. 145-51
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25084055 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150730095228 $b ABA008
999    __
$a ok $b bmc $g 1083519 $s 906174
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 70 $c 2 $d 145-51 $i 1873-488X $m Journal of pharmacological and toxicological methods $n J Pharmacol Toxicol Methods $x MED00002898
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...